Last reviewed · How we verify
Psychopharmacological treatment
Psychopharmacological treatment is a Small molecule drug developed by Hospital Universitari Vall d'Hebron Research Institute. It is currently FDA-approved for Depression, Anxiety disorders, Schizophrenia and psychotic disorders.
Psychopharmacological treatment refers to the use of psychiatric medications to modulate neurotransmitter systems and alleviate symptoms of mental health disorders.
Psychopharmacological treatment refers to the use of psychiatric medications to modulate neurotransmitter systems and alleviate symptoms of mental health disorders. Used for Depression, Anxiety disorders, Schizophrenia and psychotic disorders.
At a glance
| Generic name | Psychopharmacological treatment |
|---|---|
| Sponsor | Hospital Universitari Vall d'Hebron Research Institute |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Mental Health |
| Phase | FDA-approved |
Mechanism of action
This is a broad category encompassing multiple drug classes (antidepressants, antipsychotics, anxiolytics, mood stabilizers) that work through various mechanisms including serotonin reuptake inhibition, dopamine antagonism, or GABAergic enhancement. The specific mechanism depends on the individual drug within the psychopharmacological treatment class being administered.
Approved indications
- Depression
- Anxiety disorders
- Schizophrenia and psychotic disorders
- Bipolar disorder
- ADHD
- OCD
Common side effects
- Sedation
- Nausea
- Sexual dysfunction
- Weight gain
- Headache
- Insomnia
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Dynamic Networks in Depression Treatment: Mechanisms of Change in Pharmacological, Psychological and Combined Treatment of Depression (PHASE4)
- Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders (NA)
- MEOP - Multidimensional Evaluations in Oncological Psychiatry
- The PEDAL Intervention - Reducing Affective Lability in Bipolar Disorder (PHASE2)
- Schema Therapy for Patients With Chronic Treatment Resistant Depression (NA)
- REspiratory reHABilitation and PSYchiatric Comorbidities
- Efficacy of Metacognitive Training in Older Adults With Depression (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Psychopharmacological treatment CI brief — competitive landscape report
- Psychopharmacological treatment updates RSS · CI watch RSS
- Hospital Universitari Vall d'Hebron Research Institute portfolio CI
Frequently asked questions about Psychopharmacological treatment
What is Psychopharmacological treatment?
How does Psychopharmacological treatment work?
What is Psychopharmacological treatment used for?
Who makes Psychopharmacological treatment?
What development phase is Psychopharmacological treatment in?
What are the side effects of Psychopharmacological treatment?
Related
- Manufacturer: Hospital Universitari Vall d'Hebron Research Institute — full pipeline
- Therapeutic area: All drugs in Psychiatry/Mental Health
- Indication: Drugs for Depression
- Indication: Drugs for Anxiety disorders
- Indication: Drugs for Schizophrenia and psychotic disorders
- Compare: Psychopharmacological treatment vs similar drugs
- Pricing: Psychopharmacological treatment cost, discount & access